A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | MicrobiomeTrials← Back to trialsNCT07148089
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-02-23Est. Completion: 2027-06
Enrollment target: 18 participants Locations- Boston Children's Hospital, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- St. Paul's Hospital, Vancouver, British Columbia, Canada
Other microbiome trials you might be interested in
Long QT SyndromeCatecholaminergic Polymorphic Ventricular Tachycardia Type 1Catecholaminergic Polymorphic Ventricular Tachycardia Type 2
The goal of this observational study is to evaluate exercise testing and daily physical activity in children and adolesc…
London, United KingdomCompleted May 31, 2026
Catecholaminergic Polymorphic Ventricular Tachycardia
This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-473…
San Francisco, United StatesEst. completion Apr 2027